AI Article Synopsis
Article Abstract
Artificial Intelligence and Natural Language Processing technology have demonstrated significant promise across several domains within the medical and healthcare sectors. This technique has numerous uses in the field of healthcare. One of the primary challenges in implementing ChatGPT in healthcare is the requirement for precise and up-to-date data. In the case of the involvement of sensitive medical information, it is imperative to carefully address concerns regarding privacy and security when using GPT in the healthcare sector. This paper outlines ChatGPT and its relevance in the healthcare industry. It discusses the important aspects of ChatGPT's workflow and highlights the usual features of ChatGPT specifically designed for the healthcare domain. The present review uses the ChatGPT model within the research domain to investigate disorders associated with the hepatic system. This review demonstrates the possible use of ChatGPT in supporting researchers and clinicians in analyzing and interpreting liver-related data, thereby improving disease diagnosis, prognosis, and patient care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-024-08659-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What are the challenges that social prescribers face when supporting people within dementia and how can these be addressed? A qualitative study.
PLoS One
January 2025
Research Department of Primary Care & Population Health, Centre for Ageing Population Studies, University College London, London, United Kingdom.
Introduction: Evidence suggests that social prescribing might have a positive impact on identity, control, creativity and quality of life in people with dementia. While evidence on the benefits of social prescribing is accumulating, there is a sparsity of research on the experiences of social prescribers. This study aims to identify the challenges that social prescribers face when supporting people with dementia and their families and strategies to address these.
View Article and Find Full Text PDFEconomic impact and clinical benefits of clinical pharmacy interventions: A six-year multi-center study using an innovative medication management tool.
PLoS One
January 2025
Cleopatra Hospital, Cleopatra Hospitals Group-(CHG), Cairo, Egypt.
Background: Increasing healthcare costs, particularly in Low- and Middle-Income Countries (LMICs) like Egypt, highlight the need for rational economic strategies. Clinical pharmacy interventions offer potential benefits by reducing drug therapy problems and associated costs, thereby supporting healthcare system sustainability.
Objective: This study evaluates the economic impact and clinical benefits of clinical pharmacy interventions in four tertiary hospitals in Egypt by implementing an innovative tool for medication management, focusing on cost avoidance and return on investment (ROI), while accounting for case severity and drug therapy problem (DTP) resolution.
Prevalence and Mitigation of Cardiovascular Disease Risk Factors Among the Corporate Workforce in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.
Cureus
December 2024
Acute Medicine, Mid and South Essex NHS Foundation Trust, Southend on Sea, GBR.
Cardiovascular disease (CVDs) is the leading cause of mortality worldwide. Corporate workplaces have been identified as important environmental factors that can increase the risk and severity of CVDs. Evidence indicates that the risk and severity of CVDs can be effectively reduced by mitigating modifiable behavioural and intermediate risk factors.
View Article and Find Full Text PDFAmyloid-related changes in fluency in patients with subjective cognitive decline.
Alzheimers Dement (Amst)
January 2025
Alzheimer Center Amsterdam, Neurology Amsterdam University Medical Center Amsterdam the Netherlands.
Introduction: We examined semantic and phonemic fluency in individuals with subjective cognitive decline (SCD) in relation to amyloid status and clinical progression.
Methods: A total of 490 individuals with SCD (62 ± 8 years, 42% female, 28% amyloid-positive, 17% clinical progression) completed annual fluency assessments (mean ± SD follow-up 4.3 ± 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!